Eisai starts phase 3 trials for second Alzheimer’s drug after first’s failure

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer’s treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer’s drug, aducanumab.

…read more

Source:: Reuters – Business News